DRUG TOXICITY MECHANISMS IN HUMAN HEPATOMA HEPG2 CELLS - CYCLOSPORINE-A AND TAMOXIFEN

被引:20
作者
DUTHIE, SJ
MELVIN, WT
BURKE, MD
机构
[1] UNIV ABERDEEN,MARISCHAL COLL,DEPT BIOMED SCI,ABERDEEN AB9 1AS,SCOTLAND
[2] UNIV ABERDEEN,MARISCHAL COLL,DEPT CELL & MOLEC BIOL,ABERDEEN AB9 1AS,SCOTLAND
关键词
D O I
10.3109/00498259509061915
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Mechanisms of drug toxicity operating in human HepG2 hepatoma cells have been assessed using cyclosporin A (CsA) and tamoxifen as examples. 2. Either 150 mu M CsA or 50 mu M tamoxifen caused approximately 50% loss of HepG2 cell viability. alpha-Tocopherol (32 mu M) almost completely prevented cell death due to either CsA or tamoxifen. Tamoxifen stimulated malondialdehyde formation. The toxicity of CsA but not tamoxifen was increased by the glutathione synthesis inhibitor, buthionine-S,R-sulphoximine, and decreased by the glutathione precursor, L-cysteine. Thus, while both CsA and tamoxifen toxicities involved lipid peroxidation, reduced glutathione (or sulphydryl groups) protected against CsA but not tamoxifen. 3. CsA was metabolized to M1 and/or M17 in HepG2 cells. The effects of the cytochrome P450 inhibitors, ketoconazole and metyrapone, indicated that P450 played a role in the toxicity of CsA but not tamoxifen. The effects of superoxide dismutase and cytochrome c indicated that tamoxifen toxicity involved superoxide formation. 4. These results show that several oxidative mechanisms of drug toxicity operate in HepG2 cells.
引用
收藏
页码:1151 / 1164
页数:14
相关论文
共 72 条
[1]   ALPHA-TOCOPHEROL PREVENTS CYCLOSPORINE A-MEDIATED ACTIVATION OF PHOSPHOLIPASE A(2) AND INHIBITION OF NA+,K+-ADENOSINE TRIPHOSPHATASE-ACTIVITY IN CULTURED HAMSTER RENAL TUBULAR CELLS [J].
ANDERSON, R ;
VANRENSBURG, CEJ ;
MYER, MS .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 125 (02) :176-183
[2]  
ANUFORO DC, 1978, IN VITRO CELL DEV B, V14, P981
[3]  
Archakov A.A., 1990, CYTOCHROME P450 ACTI
[4]   EVIDENCE FOR SUPEROXIDE GENERATION BY NADPH-CYTOCHROME-C REDUCTASE OF RAT-LIVER MICROSOMES [J].
AUST, SD ;
ROERIG, DL ;
PEDERSON, TC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1972, 47 (05) :1133-&
[5]   MODULATION OF METABOLISM IN HEPG2 CELLS UPON TREATMENT WITH CYCLOSPORINE-A AND NVA2-CYCLOSPORINE [J].
BACKMAN, L ;
APPELKVIST, EL ;
SUNDBERG, A ;
TECLEBRHAN, H ;
BRUNK, U .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1991, 54 (03) :242-254
[6]   INFLUENCES OF GINKGO-BILOBA ON CYCLOSPORINE-A INDUCED LIPID-PEROXIDATION IN HUMAN LIVER-MICROSOMES IN COMPARISON TO VITAMIN-E, GLUTATHIONE AND N-ACETYLCYSTEINE [J].
BARTH, SA ;
INSELMANN, G ;
ENGEMANN, R ;
HEIDEMANN, HT .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (10) :1521-1526
[7]  
BERNHEIM F, 1948, J BIOL CHEM, V174, P257
[8]   TAMOXIFEN AND LIVER-DAMAGE [J].
BLACKBURN, AM ;
AMIEL, SA ;
MILLIS, RR ;
RUBENS, RD .
BRITISH MEDICAL JOURNAL, 1984, 289 (6440) :288-288
[9]   EFFECT OF ENZYME-INDUCTION ON SANDIMMUN (CYCLOSPORINE-A) BIOTRANSFORMATION AND HEPATOTOXICITY IN CULTURED RAT HEPATOCYTES AND INVIVO [J].
BOUIS, P ;
BROUILLARD, JF ;
FISCHER, V ;
DONATSCH, P ;
BOELSTERLI, UA .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (02) :257-266
[10]   EFFECT OF KETOCONAZOLE ON HEPATIC OXIDATIVE DRUG-METABOLISM [J].
BROWN, MW ;
MALDONADO, AL ;
MEREDITH, CG ;
SPEEG, KV .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :290-297